1 unchanged sentence
Evaluation of Disclosure Controls and Procedures
−Removed: We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time period specified in the SEC's rules and forms, and that such information is accumulated and communicated to management including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
+Added: We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time period specified in the SEC's rules and forms, and that such information is accumulated and
+Added: communicated to management including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
As of December 31, 2025, we carried out an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934.
16 unchanged sentences
Director and Officer Trading Arrangements
−Removed: No officers or directors, as defined in Rule 16a-1(f), adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement ,” as defined in Regulation S-K Item 408, during the last fiscal quarter.
+Added: During the last fiscal quarter, the following directors and “officers,” as defined in Rule 16a-1(f) of the Exchange Act, adopted a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K:
+Added: On December 26, 2025 , Joanne Donovan , Chief Medical Officer , adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of up to 125,361 shares of our common stock.
+Added: The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c).
+Added: The duration of the trading arrangement is until December 28, 2026 , or earlier if all transactions under the trading arrangement are completed.
+Added: No other directors or “officers,” as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K, during the last fiscal quarter.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
55 unchanged sentences
Offer Letter between the Registrant and Joanne Donovan, M.D., Ph.D.
−Removed: Offer Letter between the Registrant and Marc Semigran, M.D.
−Removed: February 23, 2023
+Added: Offer Letter between the Registrant and Robert Blaustein, M.D., Ph.D.
+Added: March 3, 2025
+Added: Offer Letter between the Registrant and Michael Nofi.
+Added: November 10, 2025
Executive Incentive Compensation Plan.
8 unchanged sentences
Sales Agreement, dated May 10, 2024, by and between the Registrant and Leerink Partner LLC.
−Removed: Offer Letter between the Registrant and Robert Blaustein, M.D., Ph.D.
+Added: Letter Agreement between the Registrant and R.
+Added: Michael Carruthers.
Filed herewith
Insider Trading Policy
−Removed: Filed herewith
+Added: March 3, 2025
Consent of Independent Registered Public Accounting Firm.
24 unchanged sentences
Indicates management contract or compensatory plan.
−Removed: Portions of this exhibit have been redacted in compliance with Regulation S-K Ite 601(a)(6).
+Added: Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6).
The certifications attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.
Form 10-K Summary
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.
−Removed: March 3, 2025
+Added: Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
+Added: February 26, 2026
EDGEWISE THERAPEUTICS, INC.
2 unchanged sentences
(Principal Executive Officer)
−Removed: Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
/s/ Kevin Koch
President, Chief Executive Officer and Director
−Removed: March 3, 2025
+Added: February 26, 2026
Kevin Koch, Ph.D.
(Principal Executive Officer)
−Removed: Michael Carruthers
+Added: /s/ Michael Nofi
Chief Financial Officer
−Removed: March 3, 2025
−Removed: Michael Carruthers
+Added: February 26, 2026
(Principal Financial and Accounting Officer)
1 unchanged sentence
Co-Founder, Chairman and Director
−Removed: March 3, 2025
+Added: February 26, 2026
Peter Thompson, M.D.
1 unchanged sentence
Chief Scientific Officer and Director
−Removed: March 3, 2025
+Added: February 26, 2026
Alan Russell, Ph.D.
/s/ Laura A.
−Removed: March 3, 2025
+Added: February 26, 2026
/s/ Badreddin Edris
Co-Founder and Director
−Removed: March 3, 2025
+Added: February 26, 2026
Badreddin Edris, Ph.D.
/s/ Jonathan Fox
−Removed: March 3, 2025
+Added: February 26, 2026
Jonathan Fox, M.D., Ph.D., FACC
+Added: /s/ Christopher Martin
+Added: February 26, 2026
+Added: Christopher Martin
/s/ Arlene Morris
−Removed: March 3, 2025
+Added: February 26, 2026
Arlene Morris
/s/ Jonathan Root
−Removed: March 3, 2025
+Added: February 26, 2026
Jonathan Root, M.D.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.